Programming

BCVS Scientific Sessions 2017
Basic Cardiovascular Sciences

July 10–13, 2017
Portland, Oregon
Registration Information
Watch this space for 2018 information

 


See Registration Rates and Housing Rates
 
Abstract Submission
Abstract submission is now closed.




About this Meeting

The 13th annual BCVS 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.

The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.

Target Audience

  • Basic cardiovascular scientists
  • Molecular/cellular biologists
  • Physiologists
  • Translational investigators
  • Clinical trialists
  • Practicing cardiologists
  • Cardiovascular nurses and pharmacists
In addition, the symposium will be of great value to scientists and executives of pharmaceutical companies and biotechnology firms who are in the cardiovascular space.

Learning Objectives

At the conclusion of the conference, participants will be able to:
  1. Discuss advances in the underlying mechanisms that contribute to pathological cardiac remodeling and development of targeted therapeutic strategies to improve outcomes for patients with CVD.
     
  2. Evaluate the most recent evidence on the pathophysiological mechanisms underlying myocardial perfusion injury, supporting the use of cardioprotective strategies, including advances in oxidative stress-activated mechanisms in CVD pathophysiology.
     
  3. Discuss recent advances in understanding the complex interplay between signal transduction cascades in modulating apoptotic and functional pathways (mitochondrial, ion channels, metabolism) to identify novel drug targets and preserve functional cardiac myocytes.
     
  4. Describe current research exploring the integrated role of novel "omics" technologies and "big data" analytics that may allow for precision medicine and may improve patient outcomes by examining more holistically the pathophysiological mechanisms underlying cardiovascular function.
     
  5. Discuss the importance of state-of-the-art clinically relevant reprogrammed human cellular and large animal model systems, including the challenges to bridge the gap between basic science and clinical application of these modalities for improving translational research and outcomes in patients with CVD.
     
  6. Discuss challenges and issues arising regarding the pursuit of cardiovascular research, including future research directions, issues of responsibility in research and the move towards translation into clinical practice.
     
  7. Describe recent and emerging advances into the genetic and molecular mechanisms driving cardiomyopathy and heart failure that are guiding the development of interventions such as targeted gene therapy and regenerative stem cell therapy.

BCVS Program Committee Co-Chairs

  • Michael S. Kapiloff, MD, PhD, FAHA, University of Miami Miller School of Medicine, Miami, FL
  • Jennifer Van Eyk, PhD, FAHA, Cedars Sinai Medical Center, Los Angeles, CA
  • Rong Tian, MD, PhD, FAHA, University of Washington, Seattle, WA

BCVS 2017 Program Committee Members

  • Ju Chen, PhD, UCSD School of Medicine, La Jolla, California
  • Raj Kishore, PhD, FAHA, Temple University School of Medicine, Philadelphia, Pennsylvania
  • Maria Kontaridis, PhD, FAHA, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • Xin Ma, MD, PhD, FAHA, Thomas Jefferson University, Philadelphia, Pennsylvania
  • Junichi Sadoshima, MD, PhD, FAHA, UMDNJ New Jersey Medical School, Newark, New Jersey
  • Jil Tardiff, MD, PhD, FAHA, University of Arizona, Tucson, Arizona
  • Joseph C. Wu, MD, PhD, FAHA, Stanford University School of Medicine, Stanford, California
  • Jianyi "Jay" Zhang, MD, PhD, FAHA, The University of Alabama at Birmingham, Birmingham, Alabama
  • Wolfram-Hubertus Zimmermann, PhD, FAHA, University Medical Center Göttingen, Göttingen Germany